Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2- negative breast cancer.

Autor: Al Mahmasani, Layal, Amhaz, Ghid, Zeidane, Reine Abou, Chamseddine, Nathalie, Hatab, Taha, Sabbagh, Saad, Charafeddine, Maya, Assi, Hazem I.

Publikováno v: Frontiers in Oncology; 2023, p1-8, 8p

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).

Autor: Assi HI; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Zerdan MB; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Hodroj M; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Khoury M; Department of Internal Medicine, Division of Hematology and Oncology, Hotel Dieu de France University Hospital, Beirut, Lebanon., Naji NS; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Amhaz G; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Zeidane RA; Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., El Karak F; Department of Internal Medicine, Division of Hematology and Oncology, Hotel Dieu de France University Hospital, Beirut, Lebanon.

Publikováno v: Oncotarget [Oncotarget] 2023 May 26; Vol. 14, pp. 517-525. Date of Electronic Publication: 2023 May 26.